

# DYNAMICS OF CONSUMPTION OF MACROLIDE ANTIBACTERIAL DRUGS IN UKRAINE

Yemets O. I., Matyashova N. O.

National University of Pharmacy, Kharkiv, Ukraine

ph-econom@nuph.edu.ua

**Introduction.** In recent decades the world has become a serious problem of pathogens resistance to antimicrobial agents. This situation can be seen as a threat to national security and cause a lot of social and economic harm. Microorganisms cause infectious diseases since the dawn of humanity and continue this process despite the scientific and practical progress in their treatment around the world. Macrolides are widely used in clinical practice more than half century and have proven themselves as highly effective and one of the safest antibiotics.

**Materials and methods.** To determine the volume of consumption of macrolides ATC/DDD-methodology and data of volumes of preparations realization in the system "Pharmaceuticals" of company Morion for 2013-2014 years were used.

**The results of research.** In the pharmaceutical market of Ukraine 7 INNs of macrolides and 156 TNs (2014) were presented. In term of consumption DDDs/1000 inhabitants/day (DIDs) on 01.01.2015 the preparations can be arranged in the following order: Azithromycin (1.081) > Clarithromycin (0.321) > Midecamycin (0.041) > Erythromycin (0.036) > Spiramycin (0.025) > Josamycin (0.017) > Roxithromycin (0.005). Also, analysis of the dynamics of macrolides consumption in Ukraine showed, that in the period 2013-2014 it slightly decreased from 1.54 DIDs (2013) to 1.53 DIDs (2014). In comparison with the Russian Federation dynamics of consumption also slightly decreased from 2.439 DIDs (2013) to 2.433 DIDs (2014): Azithromycin (1.576 DIDs), > Clarithromycin (0.572 DIDs) > Josamycin (0.110 DIDs) > Midecamycin (0.092 DIDs) > Erythromycin (0.061 DIDs) > Spiramycin (0.014 DIDs) > Roxithromycin (0.008 DIDs). Annual sales of macrolide antibacterial agents in 2014 were 5 228 664 packages or 25 232 557 dollars. The leader was Azithromycin, which took over 65% of the value of consumption and 74% of the number of packages in Ukraine and in Russia - 26 070 268 packages and 158 273 986 dollars (58% market share of value terms and 69% of the number of packages).

**Conclusion.** In Ukraine consumption of macrolides slightly changed from 1.54 DIDs (in 2013) to 1.53 DIDs (in 2014). Approximately the same trend was observed in the Russian Federation, indicating that the demand for these drugs is preserved. The leader of consumption in both Ukrainian and Russian pharmaceutical markets is macrolide Azithromycin.